Technical Analysis for HOOK - HOOKIPA Pharma Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Up | Up | Up |
| Historical HOOK trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 20 DMA Support | Bullish | 0.42% | |
| Crossed Above 20 DMA | Bullish | 1.35% | |
| Crossed Above 50 DMA | Bullish | 1.35% | |
| Outside Day | Range Expansion | 1.35% | |
| Fell Below 20 DMA | Bearish | 3.00% | |
| Fell Below 50 DMA | Bearish | 3.00% | |
| Cup with Handle | Other | 3.00% | |
| Crossed Above 20 DMA | Bullish | 2.04% | |
| Crossed Above 50 DMA | Bullish | 2.04% | |
| Cup with Handle | Other | 2.04% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
| Alert | Time | |
|---|---|---|
| 20 DMA Support | 14 minutes ago | |
| Up 1% | about 1 hour ago | |
| 1.5x Volume Pace | about 2 hours ago | |
| Down 1% | about 23 hours ago | |
| 60 Minute Opening Range Breakdown | about 24 hours ago |
Get this analysis on your stocks daily!
- Earnings date: 11/12/2020
HOOKIPA Pharma Inc. Description
HOOKIPA Pharma Inc., a clinical-stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase 2 clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in preclinical studies for the treatment of human papillomavirus-positive cancers. The company has a collaboration with Gilead Sciences, Inc. to develop arenavirus based therapeutics to treat hepatitis B virus and human immunodeficiency virus infections. HOOKIPA Pharma Inc. was founded in 2011 and is headquartered in New York, New York.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biopharmaceutical Cancer Life Sciences Infectious Diseases Cancers Hepatitis B Immunodeficiency Transplantation Hepatitis B Virus Viral Disease Papillomavirus Gilead Sciences Immunotherapeutics Kidney Transplant
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 13.68 |
| 52 Week Low | 5.8 |
| Average Volume | 133,173 |
| 200-Day Moving Average | 10.81 |
| 50-Day Moving Average | 11.65 |
| 20-Day Moving Average | 11.87 |
| 10-Day Moving Average | 11.91 |
| Average True Range | 0.63 |
| ADX | 11.24 |
| +DI | 19.63 |
| -DI | 18.26 |
| Chandelier Exit (Long, 3 ATRs ) | 10.80 |
| Chandelier Exit (Short, 3 ATRs ) | 11.88 |
| Upper Bollinger Band | 12.42 |
| Lower Bollinger Band | 11.31 |
| Percent B (%b) | 0.57 |
| BandWidth | 9.35 |
| MACD Line | 0.05 |
| MACD Signal Line | 0.07 |
| MACD Histogram | -0.0242 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 12.70 | ||||
| Resistance 3 (R3) | 12.70 | 12.45 | 12.58 | ||
| Resistance 2 (R2) | 12.45 | 12.26 | 12.45 | 12.54 | |
| Resistance 1 (R1) | 12.20 | 12.14 | 12.08 | 12.20 | 12.49 |
| Pivot Point | 11.95 | 11.95 | 11.89 | 11.95 | 11.95 |
| Support 1 (S1) | 11.70 | 11.76 | 11.57 | 11.70 | 11.41 |
| Support 2 (S2) | 11.45 | 11.64 | 11.45 | 11.36 | |
| Support 3 (S3) | 11.20 | 11.45 | 11.32 | ||
| Support 4 (S4) | 11.20 |
